☆ 4.7 Review

Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials

JOURNAL OF CLINICAL MEDICINE (2021)

Related references

Note: Only part of the references are listed.

Review Cardiac & Cardiovascular Systems

Supracardiac atherosclerosis in embolic stroke of undetermined source: the underestimated source

George Ntaios et al.

Summary: ESUS refers to patients with embolic stroke of undetermined source, which may be mainly caused by covert atrial fibrillation or atherosclerotic plaques. Advanced imaging methods can aid in identifying high-risk plaques. The role of novel antithrombotic strategies in these patients needs further evaluation in randomized controlled trials.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Article Critical Care Medicine

Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm

Sonali Narain et al.

Summary: In patients with COVID-19 cytokine storm (CCS), combination therapy of corticosteroids and tocilizumab demonstrates superior survival outcomes. Additionally, corticosteroids, whether used alone or in combination with tocilizumab or anakinra, are associated with reduced mortality in CCS patients.

CHEST (2021)

Add to Collection

Review Immunology

Decreased Mortality in Coronavirus Disease 2019 Patients Treated With Tocilizumab: A Rapid Systematic Review and Meta-analysis of Observational Studies

Jishnu Malgie et al.

Summary: This systematic review found that COVID-19 patients treated with tocilizumab (TCZ) had lower mortality rates compared to those not treated with TCZ. However, there were no significant differences observed in terms of side effects between the two groups.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Review Virology

Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis

Muhammad Aziz et al.

Summary: The efficacy of tocilizumab in severe COVID-19 patients appears to reduce mortality and the need for mechanical ventilation. Further randomized controlled trials are required to confirm these findings.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial

Olivier Hermine et al.

Summary: In this clinical trial of COVID-19 patients with pneumonia requiring oxygen support but not in the ICU, tocilizumab did not reduce WHO-CPS scores below 5 by day 4 but may have reduced the risk of needing noninvasive ventilation, mechanical ventilation, or death by day 14. There was no difference in mortality by day 28. Further studies are needed to confirm these preliminary results.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia A Randomized Clinical Trial

Carlo Salvarani et al.

Summary: This study evaluated the use of tocilizumab in hospitalized COVID-19 pneumonia patients and found no significant benefit compared to standard care. Further randomized clinical trials with blinded, placebo-controlled methods are needed to confirm these results and explore potential applications of tocilizumab in different stages of the disease.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Article Hematology

Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality-Brief Report

Axel Rosell et al.

Summary: The study found that COVID-19 patients have significantly higher levels of circulating EV TF activity compared to healthy controls. This increased activity was associated with disease severity, mortality, and markers like D-dimer, indicating a potential role of EV TF in driving thrombosis in COVID-19 patients.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study

Ismael Francisco Aomar-Millan et al.

Summary: The study investigated the use of anakinra in patients with severe COVID-19 pneumonia and moderate hyperinflammatory state after non-response to corticosteroids or corticosteroids plus tocilizumab therapy. The results showed that treatment with anakinra was associated with a reduced risk of mortality and may improve the prognosis of these patients.

INTERNAL AND EMERGENCY MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

A. C. Kalil et al.

Summary: Combination treatment with baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Carlos Salama et al.

Summary: Among hospitalized patients with Covid-19 pneumonia not on mechanical ventilation, tocilizumab reduced the risk of progression to mechanical ventilation or death, but did not improve overall survival. There were no new safety concerns identified.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

Viviane C. Veiga et al.

Summary: The study found that in patients with severe or critical COVID-19, tocilizumab in combination with standard care was not superior to standard care alone in improving clinical outcomes at 15 days, and it might increase mortality.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Critical Care Medicine

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

Xavier Mariette et al.

Summary: The study aimed to determine the effectiveness of anakinra in improving outcomes of patients with mild-to-moderate COVID-19 pneumonia, but the results showed that anakinra did not show improvement in patient outcomes. Further studies are needed to assess the efficacy of anakinra in other selected groups of patients with more severe COVID-19.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Medicine, Research & Experimental

An immune-based biomarker signature is associated with mortality in COVID-19 patients

Michael S. Abers et al.

Summary: Immune and inflammatory responses are important factors contributing to disease severity in COVID-19. This study identified specific immune-based biomarkers associated with mortality in COVID-19 patients, with some biomarkers consistently higher in those who died compared to those who recovered, suggesting their potential for early prediction of disease outcome.

JCI INSIGHT (2021)

Add to Collection

Article Multidisciplinary Sciences

Transcriptional response modules characterize IL-1β and IL-6 activity in COVID-19

Lucy C. K. Bell et al.

Summary: The expression of IL-1 beta and IL-6 response modules can provide a dynamic readout of functional cytokine activity in vivo in COVID-19, without being associated with disease severity or mortality.

ISCIENCE (2021)

Add to Collection

Article Infectious Diseases

Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study

Belen Ruiz-Antoran et al.

Summary: A multicentre retrospective cohort study in Spain showed that the use of tocilizumab in COVID-19 patients can reduce mortality rates. Additionally, tocilizumab treatment in non-intubated patients with new-onset respiratory failure during the first 48 hours provides additional benefits on top of steroid therapy.

INFECTIOUS DISEASES AND THERAPY (2021)

Add to Collection

Review Infectious Diseases

Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis

Imad M. Tleyjeh et al.

Summary: This study reviewed the efficacy of the IL-6 receptor antagonist tocilizumab in COVID-19 patients. The results showed that tocilizumab can reduce the risk of mechanical ventilation, but its impact on short-term mortality remains inconclusive. Additionally, the use of tocilizumab does not increase the risk of infections or adverse events.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Article Medicine, General & Internal

Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies.

Laura Pasin et al.

Summary: Meta-analysis of studies on anakinra in COVID-19 patients suggests that its use may be associated with reduced mortality and need for mechanical ventilation, with no observed increase in adverse events. Further randomized clinical trials are needed to confirm these findings.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2021)

Add to Collection

Article Allergy

Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia

Emanuele Pontali et al.

Summary: The study indicates that early use of high doses of intravenous anakinra, with or without glucocorticoids, may have potential efficacy and safety in treating COVID-19 pneumonia on a larger series of patients.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

I. O. Rosas et al.

Summary: In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Anthony C. Gordon et al.

Summary: Interleukin-6 receptor antagonists tocilizumab and sarilumab were found to improve outcomes, including survival, in critically ill patients with Covid-19 receiving organ support in ICUs according to an ongoing international trial. The efficacy of these treatments has been confirmed, with patients benefiting from the therapy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Respiratory System

Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19

Fasihul A. Khan et al.

Summary: Through systematic review and meta-analysis, tocilizumab was associated with a lower relative risk of mortality in COVID-19 patients, but effects on other outcomes were inconclusive. Current evidence for the efficacy of anakinra, siltuximab or sarilumab in COVID-19 is insufficient, with further studies urgently needed for conclusive findings.

THORAX (2021)

Add to Collection

Article Biology

An open label trial of anakinra to prevent respiratory failure in COVID-19

Evdoxia Kyriazopoulou et al.

Summary: Early suPAR-guided anakinra treatment can reduce the risk of severe respiratory failure and restore the pro-/anti-inflammatory balance in COVID-19 patients. The 30-day mortality rate was lower in the anakinra treatment group compared to the control group.

ELIFE (2021)

Add to Collection

Article Critical Care Medicine

Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open- label, multicentre, randomised, controlled, phase 3 trial

Arvinder S. Soin et al.

Summary: The study recruited 180 patients and found that tocilizumab did not reduce disease progression in patients with moderate to severe COVID-19, but may have some effect in severe cases.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Infectious Diseases

Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial

Vincent Dubee et al.

Summary: A trial in France on the efficacy of hydroxychloroquine in treating COVID-19 patients was ended early due to the slowing down of the pandemic. The results showed that hydroxychloroquine did not lead to better clinical or virological outcomes compared to placebo in patients with mild to moderate COVID-19.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Article Medicine, General & Internal

Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19

George N. Dalekos et al.

Summary: Early administration of personalized combinations of immunomodulatory agents may be lifesaving in hospitalized patients with COVID-19. An immediate intervention (the sooner the better) could be helpful to avoid development of full-blown acute respiratory distress syndrome and improve survival.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

Paul M. Ridker et al.

Summary: This study investigated the safety and efficacy of IL-6 inhibition treatment in high cardiovascular risk individuals. Results showed that ziltivekimab effectively reduced biomarkers of inflammation and thrombosis, with promising effects observed in patients with chronic kidney disease.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19 A Randomized Clinical Trial

Roberto Caricchio et al.

Summary: This clinical trial compared the efficacy of canakinumab vs placebo on survival without invasive mechanical ventilation (IMV) in hospitalized patients with severe COVID-19. The results showed that treatment with canakinumab did not significantly increase the likelihood of survival without IMV compared to placebo.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

Evdoxia Kyriazopoulou et al.

Summary: The SAVE-MORE phase 3 study demonstrated the efficacy of anakinra, an IL-1 alpha/beta inhibitor, in patients with COVID-19 and high serum levels of soluble plasminogen activator receptor, showing significant reduction in clinical deterioration and decreased 28-day mortality.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

Patricia O. Guimaraes et al.

Summary: Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo. The mortality rate was lower in the tofacitinib group within 28 days. However, the rate of serious adverse events was similar in both groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Critical Care Medicine

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER) : a randomised, double-blind, parallel-group, placebo- controlled phase 3 trial

Vincent C. Marconi et al.

Summary: Although there was no significant reduction in the frequency of disease progression overall, treatment with baricitinib in addition to standard of care (including dexamethasone) had a similar safety profile to that of standard care alone, and was associated with reduced mortality in hospitalised adults with COVID-19.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: A phase I/II randomized control trial

Shaukat Ali et al.

Summary: Hyperimmune anti-COVID-19 Intravenous Immunoglobulin (C-IVIG) therapy appears to be a safe and effective treatment for severe and critical COVID-19 patients, improving survival rates and reducing disease progression.

ECLINICALMEDICINE (2021)

Add to Collection

Article Rheumatology

Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study

Giulio Cavalli et al.

Summary: IL-1 inhibition was associated with reduced mortality in patients with COVID-19 and hyperinflammation, while IL-6 inhibition showed effectiveness in patients with high C-reactive protein concentrations. Both IL-1 and IL-6 inhibition were effective in patients with low lactate dehydrogenase concentrations.

LANCET RHEUMATOLOGY (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Supracardiac atherosclerosis in embolic stroke of undetermined source: the underestimated source

George Ntaios et al.

Summary: In patients with ESUS, covert atrial fibrillation and atherosclerotic plaques in supra-aortic arteries are two significant embolic sources, with advanced imaging methods available to identify high embolic risk plaques.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Embolic Stroke of Undetermined Source JACC Review Topic of the Week

George Ntaios

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

Add to Collection

Article Microbiology

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

Evangelos J. Giamarellos-Bourboulis et al.

CELL HOST & MICROBE (2020)

Add to Collection

Letter Cardiac & Cardiovascular Systems

ST-Elevation Myocardial Infarction in Patients With COVID-19 Clinical and Angiographic Outcomes

Giulio G. Stefanini et al.

CIRCULATION (2020)

Add to Collection

Article Medical Laboratory Technology

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Cynthia Magro et al.

TRANSLATIONAL RESEARCH (2020)

Add to Collection

Letter Medicine, General & Internal

ST-Segment Elevation in Patients with Covid-19-A Case Series

Sripal Bangalore et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Letter Medicine, General & Internal

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

Thomas J. Oxley et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Medicine, General & Internal

Venous Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis

Gerald Chi et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Article Hematology

Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients With COVID-19

Jeffrey S. Berger et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Carolina Lucas et al.

NATURE (2020)

Add to Collection

Article Medicine, General & Internal

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

A. B. Cavalcanti et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Clinical Neurology

Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial

George Ntaios et al.

STROKE (2020)

Add to Collection

Article Hematology

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

F. A. Klok et al.

THROMBOSIS RESEARCH (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19 A Randomized Clinical Trial

Pierre-Francois Dequin et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial

Bruno M. Tomazini et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

Derek C. Angus et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, Research & Experimental

Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

Panagiotis Skendros et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Article Biochemistry & Molecular Biology

An inflammatory cytokine signature predicts COVID-19 severity and survival

Diane Marie Del Valle et al.

NATURE MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

John H. Stone et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19 A Randomized Clinical Trial

Wesley H. Self et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Rheumatology

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Alexander P. J. Vlaar et al.

LANCET RHEUMATOLOGY (2020)

Add to Collection

Review Hematology

Immunoinflammatory, Thrombohaemostatic, and Cardiovascular Mechanisms in COVID-19

Selin Gencer et al.

THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Review Hematology

Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis

Stephan Nopp et al.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Prevalence and Overlap of Potential Embolic Sources in Patients With Embolic Stroke of Undetermined Source

George Ntaios et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)

Add to Collection

Article Medicine, General & Internal

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction

Jean-Claude Tardif et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

P. M. Ridker et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

David Moher et al.

ANNALS OF INTERNAL MEDICINE (2009)

Add to Collection

Article Medicine, General & Internal

Measuring inconsistency in meta-analyses

JPT Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.